WALTHAM, Mass. The market for drugs that treat a cancer of the bone marrow will more than double during the 10-year period between 2008 and 2018, according to a new report by market research firm Decision Resources.
According to the report, the multiple myeloma market will have grown from $2.1 billion in 2008 to $5.3 billion by 2018 in the United States, United Kingdom, Germany, France, Spain, Italy and Japan.
Increased use of Celgene’s Revlimid (lenalidomide) and launches of such drugs as Celgene’s pomalidomide and Onyx Pharmaceuticals’ carfilzomib will mostly drive the market growth, according to the report. Revlimid, Velcade (bortezomib), made by Millennium Pharmacueticals and Johnson & Johnson, and Thalomid (thalidomide), made by Celgene and Fujimoto Seiyaku, currently dominate the market.